Trastuzumab is a humanized mAb that recognizes the fourth domain of the extracellular region of HER2 [177] and was approved in 1998 by the FDA as the first mAb for solid tumors, particularly for breast cancer treatment. Here, ERBB2 is linked to breast cancer.